Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

<p>– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP), including an enhanced response in individuals with elevated body mass index (BMI) – – Results simultaneously published in the Journal of the American Medical Association (JAMA) – – Pivotal clinical program for lorundrostat as a treatment of patients [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/mineralys-therapeutics-presents-target-htn-phase-2-trial-results-in-late-breaking-science-session-at-2023-aha-hypertension-scientific-sessions/">Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>